

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61F 13/02, 13/00	A1	(11) International Publication Number: WO 94/06383 (43) International Publication Date: 31 March 1994 (31.03.94)
(21) International Application Number: PCT/US93/08714 (22) International Filing Date: 14 September 1993 (14.09.93) (30) Priority data: 07/943,169 14 September 1992 (14.09.92) US (71) Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY [US/US]; Old Queens Building, Somerset and George Streets, New Brunswick, NJ 08903 (US). (72) Inventors: CHIEN, Yie, W. ; 5 West Lake Court, North Brunswick, NJ 08902 (US). CHEN, Guo-Shen ; No. 5 Huang Gu Shan Street, Hang Zhou, Zhejiang (CN). CHIEN, Te-Yen ; 10 Quail Court, Branchburg, NJ 08876 (US).		(74) Agent: SINN, Leroy, G.; P.O. Box 559, Oldwick, NJ 08858 (US). (81) Designated States: AU, CA, FI, JP, KP, KR, NO, NZ, PL, RU, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: TRANSDERMAL CONTROLLED DELIVERY OF PHARMACEUTICALS AT VARIABLE DOSAGE RATES AND PROCESSES (57) Abstract Transdermal polymer dosage units are provided which comprise a backing layer and a reservoir layer. The reservoir layer can have multiple regions which contact the skin during use, optionally may have different pharmaceuticals, may provide variable rate of transdermal absorption, and may provide the pharmaceuticals in the form of microreservoirs or one or more macroreservoirs. The reservoir region can comprise a macroreservoir of one or more pharmaceuticals wherein the reservoir is bounded by a backing layer and a layer of a substantially non-porous permeability-regulating polymer membrane which directly or indirectly contacts the skin during transdermal administration. Also, provided is a process of transdermal administration of pharmaceuticals using the novel dosage units.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

TRANSDERMAL CONTROLLED DELIVERY OF PHARMACEUTICALS
AT VARIABLE DOSAGE RATES AND PROCESSES

TECHNICAL FIELD

A novel transdermal absorption dosage unit by which multiple pharmaceuticals can be provided for transdermal absorption simultaneously at different or variable dosage rates and at relatively constant permeation profiles. The dosage units can provide the desired differences or variation in the dosage rates by providing multiregional areas of the dosage unit which have different compositions with respect to the pharmaceuticals. The novel dosage units of this invention can also provide controlled and variable dosage rates of two or more pharmaceuticals on a simultaneous basis from a single reservoir area. A single dosage area can comprise a reservoir in which the pharmaceuticals are in liquid state and are contained by a permeability-regulating membrane, which can come in contact either directly or indirectly with the skin of the subject being treated. The pharmaceuticals administered by the dosage unit of this invention can vary widely. Additionally, this invention relates to an improved process for transdermal systemic delivery of pharmaceuticals.

5 BACKGROUND ART

10 It has been found that certain pharmaceuticals are
15 absorbed to a degree through the skin. This is referred to
20 as transdermal absorption. One means of transdermal absorp-
25 tion has been to disperse the pharmaceutical within a poly-
30 meric disc or a container of a gel and then contacting an
35 area of the skin of the subject to be treated with the disc
40 or gel containing the pharmaceutical. Problems encountered
 in the past include adequate control over the rate and dura-
 tion of transdermal absorption or the rate can be too slow
 in the case of certain dosage forms, especially from pharma-
 ceutical-containing discs or pharmaceutical-containing gel
 container dosage units. It has been found that the trans-
 dermal absorption rates of certain pharmaceuticals can be
 increased by coadministering one or more transdermal absorp-
 tion-enhancing agents with the pharmaceutical to be absorbed
 when compounding the polymeric disc or the pharmaceutical-
 containing gel.

45 It is desired to improve the dosage unit forms or
50 devices by which pharmaceuticals are transdermally absorbed,
55 especially in view of the importance of administering phar-
 maceuticals by this means. Desired transdermal absorption
 of pharmaceuticals would provide an avoidance of gastro-
 intestinal incompatibility with the pharmaceuticals and
 unwanted destruction of the pharmaceuticals by metabolism in
 the gastrointestinal tract and by a hepatic "first-pass"
 metabolism. The transdermal absorption minimizes inter- and

5

10

15

20

25

30

35

40

45

50

55

intra-patient variations regarding such incompatibilities and metabolisms. By transdermal absorption, it is deemed possible to provide a more constant pharmaceutical concentration in the body and to realize a greater pharmacological efficacy. It is possible, by proper transdermal absorption, to reduce the frequency of dosing. Transdermal administration provides most of the advantages of intravenous dosing without the necessity of hospitalization and the accompanying discomfort and inconvenience.

It is desired to improve the administration by transdermal means of pharmaceuticals by modulating the delivery of pharmaceuticals, desirably at substantially constant rates. It is also desired to administer two or more pharmaceuticals with synergistic therapeutic activities, simultaneously, especially at variable dosage rates. For example, it is often desired in regulating fertility by administering simultaneously an estrogenic steroid, such as 17-beta-estradiol (commonly referred to as "estradiol"), and also to administer simultaneously a progestational steroid. These hormonal steroids normally have differing absorption rates and require different dosage amounts of the respective steroids. These steroids are used for either fertility regulation or for the treatment of postmenopausal syndrome and other hormonal replacement therapy.

5 It is desired to provide such improved dosage units
which enable controlled delivery of pharmaceuticals,
10 including steroidal hormones, with the possibility of two or
more pharmaceuticals being administered simultaneously at
controlled and variable dosage rates. Furthermore, it is
15 desired to provide improved methods of administration of
pharmaceuticals, including the simultaneous administration
20 of multiple pharmaceuticals with different pharmacological
activities, including hormonal activities, to achieve a
synergistic effect.
25

SUMMARY OF INVENTION

30 This invention relates to a transdermal dosage unit for
administration of one or more pharmaceuticals simultaneously
at controlled and variable rates of transdermal delivery.
35 The transdermal dosage unit provided by this invention com-
prises the following:

- 40 a) a backing layer which is impervious to the ingredients
of the dosage unit;
- 45 b) a reservoir having present for transdermal absorption
one or more pharmaceuticals, said multiple pharmaceuti-
cals being compatible and being delivered simultaneous-
50 ly, preferably at constant rates of administration,
over a predetermined duration of administration;
- 55 c) means which desirably provide variable transdermal
absorption rates of the one or multiple pharmaceuticals
in an effective amount to result in substantially con-

5

stant systemic levels continuously for at least 24 hours; and

10

- d) an adhesive means to affix said dosage unit to the intact skin of a subject receiving the therapy provided thereby.

15

20

The reservoir can be provided in multiregions, which are in contact with the skin of the subject undergoing treatment with said dosage unit, at least two of which provide transdermal absorption of one or more pharmaceuticals simultaneously from each of the regions.

25

30

The dosage unit permits two or more pharmaceuticals to be administered transdermally and simultaneously through the intact skin to achieve therapeutically effective systemic concentrations and to maintain the therapeutic concentrations at substantially constant levels continuously for at least a 24-hour period. Pharmaceuticals which are subject to hepatic "first-pass" elimination or which are irritating to the gastrointestinal tract and which have synergistic or additive effect when used in combination can be selected for administration by the dosage units of this invention. One of the combinations of pharmaceuticals which can be administered by the dosage units of this invention is a combination of progestational and estrogenic steroids, natural or synthetic, for the regulation of fertility or treatment of post-menopausal syndrome or other hormonal steroid therapy. Other possible combinations of pharmaceuticals which can

35

40

45

50

55

5 be administered by the dosage units include: (1)
10 testosterone and 17-methyl testosterone, (2) testosterone
and estradiol, (3) AZT and DDC (or DDI), (4) a propranolol
and hydrochlorothiazide, (5) bumetanide and cyclothiazide.
15 The reservoir can comprise mono- or multi-regional reservoir
compartments which are adapted to provide controlled and
20 variable delivery of two or more pharmaceuticals on a simul-
taneous basis and at rates which are substantially constant
continuously for a period of at least 24 hours or longer.
25 The mono- or multi-regional pharmaceutical reservoir com-
partment or compartments can be provided by forming the
30 reservoir between two sheets of pharmaceutical-impermeable
protective plastic laminates: the one laminate layer com-
prising a peelable release liner to be removed just before
35 application of the dosage unit to the subject of the therapy
and another layer being a backing layer to house and to pro-
40 tect the pharmaceutical reservoir compartments from the
environment as well as to control and to restrict the phar-
maceuticals to be delivered transdermally to the skin of the
45 subject being treated.

The rate of transdermal delivery can be achieved by
50 controlling the solubility of the respective pharmaceutical
or pharmaceuticals and the permeability across a permeabil-
ity-regulating membrane and the skin. The rates of trans-
55 dermal permeation can be programmed at therapeutically-
effective ratios. The solubility of the one or more pharma-

5 ceuticals administered from said dosage unit as stated above
can be provided from a single reservoir area or from mul-
10 tiple reservoir areas of the transdermal dosage unit pro-
vided hereby by changing, regulating or varying the rate of
transdermal permeation.

15 In providing the preferred dosage units of this inven-
tion, it is useful and necessary to study the differences in
20 solubility and permeability of the one or more pharmaceuti-
cals to be coadministered by the application of the dosage
units of this invention, whether they are mono- or multi-
25 regional drug reservoir compartment dosage units whereby the
one or more pharmaceuticals can be delivered transdermally
30 at variable dosage rates to achieve desired therapeutically-
effective ratio or ratios.

35 If a multiregional reservoir is used, it is desirable
that at least one region has at least one pharmaceutical
present in the form of a macroreservoir or microreservoirs.

40 If a macroreservoir form is used, it is desired that
the macroreservoir be covered by application to the pharma-
45 ceutical-releasing surface of the reservoir a permeability-
regulating polymeric membrane, which is non-porous. If
microreservoirs are used, the preferred non-porous per-
50 meability-regulating membrane is a (ethylene/vinyl acetate)
copolymer wherein the vinyl acetate content can be in the
55 range (by mean weight) of about 4.6 percent to about 50
percent; presently preferred in the mean weight range from
about 18 to about 40 percent.

5

10

15

20

25

30

It is also presently preferred that the rate of one or more of the pharmaceuticals provided by the dosage unit can be made variable, for example, by using a combination of mutually miscible, bioacceptable solvents. It has been found suitable to use, for example, certain mutually miscible, bioacceptable water-organic solvent combinations, such as certain water-ethyl alcohol combinations. It has been found preferable, for example, in simultaneous transdermal systemic delivery of an estrogen, such as estradiol, and a progestin, such as levonorgestrel, to use a water-ethyl alcohol combination wherein the content (by volume) of ethyl alcohol is about 40 to about 85 percent based on the combined volume of water and ethyl alcohol.

35

40

45

50

55

If at least one pharmaceutical is to be present in the reservoir in the form of microreservoirs of the pharmaceutical, the pharmaceutical can be dissolved in a biocompatible liquid which can provide variability of the transdermal absorption rate if desired. For example, combinations of water and polyethylene glycol or the like can be used. The pharmaceutical can be dispersed and dissolved in liquid before dispersion into a biocompatible polymeric material, such as an adhesive polymer, elastomeric polymer or gelling polymer and then stirred at sufficiently high speed to form a pharmaceutical-containing polymeric material wherein microreservoirs of the dissolved pharmaceutical are dispersed in a polymeric material. The polymer selected must

5 be biocompatible, compatible with the pharmaceuticals micro-
dispersed therein and permit the release of the pharmaceuti-
10 cals for the desired transdermal absorption.

Provided hereby also is a novel method of transdermal
absorption of pharmaceuticals using the transdermal dosage
15 units of this invention.

20 BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a dosage unit of this invention, wherein
the reservoir for the pharmaceuticals contains two pharma-
25 ceuticals, A and B, in a macroreservoir form. The macro-
reservoir is covered by a pharmaceutical permeability-regu-
lating polymer membrane. The dosage unit is shown as a
30 cross-sectional view. The dosage unit has a pressure sensi-
tive adhesive polymeric ring in a peripheral location with
35 respect to the macroreservoir containing pharmaceuticals A
and B. Shown as FIG. 1-(A) is a top view of the dosage unit
40 of FIG. 1.

FIG. 2 shows a dosage unit of this invention similar to
that shown in FIG. 1 and FIG. 1-(A) with the exception that
45 the peripheral ring is made of a polymeric adhesive material
and comprises a microreservoir containing pharmaceutical B.
50 The central compartment A consists of a macroreservoir con-
taining pharmaceutical A. FIG. 2-(A) represents a top view
of the dosage unit of FIG. 2 shown in cross-sectional view.
55

5 FIGS. 3A and 3B show the permeation profile of levonorgestrel as it is varied, depending upon the amount of
10 ethanol present in a water-ethanol combination as compared to 100% water and 100% ethanol.

15 FIG. 4 shows the variation in the skin permeation rate of levonorgestrel dependent upon the concentration of ethanol in water on a volume/volume percent basis.

20 FIG. 5 is a graph showing the difference in levonorgestrel permeation rate depending upon the weight percent of vinyl acetate in the permeability-regulating (ethylene/vinyl acetate) copolymer membrane in a dosage unit as shown in
25 FIG. 1 and 2.

30 FIG. 6 is a graph showing the effect of the vinyl acetate content in the permeability-regulating membrane consisting of a (ethylene/vinyl acetate) copolymer upon the
35 permeation rate of levonorgestrel across hairless rat skin.

40 FIG. 7 is a graph which shows the difference in the skin permeation profile of levonorgestrel vs. the thickness of a permeation-regulating (ethylene/vinyl acetate) copolymer membrane in a dosage unit of the type shown in FIGS. 1
45 and 2 as compared with the permeation rate wherein no membrane is in contact with the skin.

50 FIG. 8 is a graph which shows the relationship between the skin permeation rate of levonorgestrel across the permeability-regulating membrane utilizing a (ethylene/vinyl acetate) copolymer membrane containing 28% vinyl acetate and
55 wherein the macroreservoir solution contains 70% ethanol, as

5
10 solubilizer, 2% oleic acid, as skin permeation-enhancing agent, and 28% water on a volume/volume basis. The dosage unit utilized in this evaluation is of the type shown in FIGS. 1 and 2.

15 FIG. 9 is a graph which shows the skin permeation rate of levonorgestrel (in mcg/cm²/hr) from a macroreservoir solution containing varying ratios of ethanol and water on a
20 v/v basis and also shows how the absorption is affected by the presence of five percent of two different skin permeation-enhancing agents. The dosage unit utilized in this
25 evaluation is of the type shown in FIGS. 1 and 2.

30 FIG. 10 is a graph which shows the change in skin permeation rate of levonorgestrel from a saturated levonorgestrel reservoir solution having a 70:30 ethanol:water ratio
35 on a V/V basis. The dosage unit used is of the type shown in FIGS. 1 and 2. The vinyl acetate content in the permeability-controlling (ethylene/vinyl acetate) copolymer
40 membrane is 28% and the thickness of the membrane is 50 microns. The rate of permeation is shown to increase as the
45 concentration of oleic acid (as the skin permeation-enhancing agent) is increased.

50 FIG. 11 is a graph showing the effect of estradiol loading dose on the permeation rate across the hairless rat skin covered with permeability-regulating (ethylene vinyl
55 acetate) copolymer membrane wherein the vinyl acetate content is 28 percent and the thickness of the membrane is 50

5 microns. Hairless rat skin was utilized in this evaluation.
The reservoir solution used is a saturated levonorgestrel
10 solution wherein the ethanol concentration is 70 percent and
the concentration of oleic acid as the skin permeation-
enhancing agent is 2 percent. Permeation rates are shown
15 for estradiol and levonorgestrel, in which permeation rate
of estradiol varies as a function of the loading dose of
estradiol in the solution. A dosage unit of the type shown
20 in FIG. 1 is utilized in this evaluation.

FIG. 12 is a graph showing the effect of estradiol
25 loading dose on the ratio of skin permeation rates of levo-
norgestrel over estradiol. In the evaluation, a permeabil-
ity-regulating (ethylene/vinyl acetate) membrane having a
30 vinyl acetate content of 28 percent and a thickness of 50
microns is used. The hairless rat skin test is utilized as
35 well as the saturated levonorgestrel concentration in 70
percent ethanol and 2 percent oleic acid, as the enhancer,
40 are used.

FIG. 13 is a graph which shows estradiol permeation
45 profiles from a dosage unit such as the one shown in FIG. 1
utilizing the test procedure in which human cadaver skin is
covered with a permeability-regulating (ethylene/vinyl ace-
50 tate) copolymer membrane. The skin permeation of estradiol
is from a reservoir solution having levonorgestrel at
saturation concentration. Various estradiol concentrations
55 are utilized in the comparative testing, with estradiol
loadings varying from 0.2 to 10 milligrams/milliliter and to

5 saturation concentration. A dosage unit of the type shown
10 in FIG. 1 is used.

15 FIG. 14 is a graph which shows a permeation profile of
levonorgestrel across a permeability-regulating (ethylene/
vinyl acetate) copolymer membrane covered human cadaver
20 skin. The dosage unit utilized is of the type shown in FIG.
1. Varying estradiol concentrations are used in the reser-
voir solution varying from 0.2 mg/ml to saturation.

25 FIG. 15 is a graph showing the effect of estradiol
loading in a dosage unit as shown in FIG. 1 on the permea-
tion rates of estradiol and levonorgestrel across a per-
meability-controlling membrane utilizing an (ethylene/vinyl
30 acetate) copolymer membrane. The evaluation is done in the
absorption test utilizing human skin. The donor solution
35 contained in the macroreservoir is saturated with levonor-
gestrel, contains 2 percent oleic acid as an enhancing agent
and has 70 percent ethanol and 28 percent water.

40 FIG. 16 is a graph showing the effect of estradiol
loading on the ratio of the permeation rates of levonorges-
45 trel over estradiol. The permeability-controlling membrane
of (ethylene/vinyl acetate) copolymer is utilized wherein
the vinyl acetate content is 28 percent and the thickness is
50 50 microns. Levonorgestrel is present at saturated condi-
tion. Two percent oleic acid and 70 percent ethanol are
55 utilized in the aqueous reservoir solution. Human cadaver
skin is used in the absorption test.

FIG. 17 is a graph showing the effect of variation in the ratio the pharmaceutical-releasing area in a dosage unit of the type shown in FIG. 2 on the dosage rate ratio of levonorgestrel/estradiol. Levonorgestrel is present in the macroreservoir wherein the reservoir solution is 70 percent ethanol and 30 percent water. The permeability-controlling membrane is a (ethylene vinyl acetate) membrane having 28 percent vinyl acetate and a thickness of 50 microns. Estradiol is present in the peripheral ring reservoir as a micro-reservoir of estradiol wherein the polymeric material used is a polyacrylate.

FIG. 18 shows a dosage unit wherein two distinct reservoirs are present, the reservoirs having pharmaceuticals A and B, respectively. The reservoirs have the pharmaceuticals present in a matrix form.

DETAILED DESCRIPTION OF THE INVENTION AND THE PREFERRED EMBODIMENTS

The backing layer can be made of any suitable material which is impermeable to the pharmaceuticals dispersed within the adjacent reservoir layer. The backing layer serves as a protective cover and provides also a support function. The backing can be formed so that it is essentially the same size layer as the central reservoir containing one or more pharmaceuticals or it can be of larger dimension so that it can extend beyond the side of the central reservoir or overlay the side or sides of the reservoir and then can extend

5 outwardly in a manner that the surface of the extension of
the backing layer can be a base for a pressure-sensitive
10 adhesive ring to hold the dosage unit in intimate contact
with the skin of the subject treated.

15 Examples of materials suitable for making the backing
layer are films of high and low density polyethylene, poly-
propylene, polyvinylchloride, polyesters such as poly (ethy-
20 lene phthalate), metal foils, metal foil laminates of such
suitable polymer films, and the like. Preferably, the mate-
25 rials used for the backing layer are laminates of such poly-
mer films with a metal foil such as aluminum foil. In such
laminates, a polymer film of the laminate will usually be in
30 contact with the pharmaceutical-containing reservoir. The
backing layer can be any appropriate thickness which will
35 provide the desired protective and support functions. A
suitable thickness will be from about 10 to about 200
microns. Desirably, the thickness will be from about 15 to
40 about 150 microns, and preferably be from about 20 to about
100 microns.

45 In illustration of the dosage units provided by this
invention, the FIG. 1 dosage unit is provided. The backing
layer is selected from the above illustrative backing layer
50 pharmaceutical-impermeable laminates. It has been found
suitable to use as backing layer consisting of a laminate of
aluminum foil and polyester film which is heat sealable,
55 such as sold by 3M as Scotch Pak 1009. A non-porous mem-
brane such as a non-porous (ethylene/vinyl acetate) copoly-

5

10

15

20

25

30

35

40

45

50

mer film, which is bioacceptable, can be used as the permeability-regulating membrane. The non-porous (ethylene/vinyl acetate) copolymer film can be precast on a siliconized paper or other substrates to provide a receptacle of suitable dimensions to form the walls of the reservoir. To this reservoir receptacle is added the desired form of one or more pharmaceuticals. The pharmaceuticals can be dissolved in a solution for the pharmaceuticals and added in a suitable amount to the reservoir receptacle. Then, a sheet of the backing layer is selected. It is placed over the reservoir receptacle and heat sealed thereto. It has been found that a sealing temperature of about 350-400°F, such as 370°F, can ordinarily be used and a sealing pressure of 50 psi is suitable. The sealing conditions can be varied widely depending upon the thermal characters of the backing layer and permeability-regulating membrane used. The backing layer can extend around the sides of the reservoir receptacle. On a siliconized release liner using a pattern to form a peripheral adhesive ring, a peripheral ring of adhesive polymer is formed. This adhesive polymer ring mounted on the siliconized release liner is mounted and sealed to the outwardly extending portion of the backing layer.

55

The adhesive polymer used in forming the ring can have a pharmaceutical microdispersed therein, for example, by dissolving the pharmaceutical in a biocompatible solution

5 and then stirring at a sufficiently high intensity to cause
the pharmaceutical to be microdispersed in the adhesive
10 polymer to form microreservoirs.

The one or more pharmaceuticals present in the reser-
voirs can be selected from a wide variety. If desired, a
15 gelling agent can be added to the macroreservoir solution to
provide the macroreservoir in a semi-solid state. Also, the
20 macroreservoir solution can be also microdispersed within an
adhesive polymer as described above in connection with for-
mation of the peripheral ring of the FIG. 1 dosage unit.
25 This results in the pharmaceutical component of the reser-
voir to be provided as microreservoirs of the pharmaceuti-
cal.
30

The dosage units provided thereby can be stored appro-
priately until it is desired to treat a subject with the
35 dosage unit whereupon after removal of the peelable release
liner, it is applied to the skin of the subject.

40 FIG. 1-(A) shows the top view of the dosage unit of
FIG. 1.

45 FIG. 2 is substantially the same dosage unit design as
provided by FIG. 1 with the exception that the pharmaceuti-
cal A is contained in the macroreservoir compartment (drug-
50 reservoir compartment A) and pharmaceutical B is present in
microreservoir form in the peripheral adhesive ring (drug-
reservoir compartment B). Provided is FIG. 2(A) showing the
55 top view of the dosage unit of FIG. 2.

5 The permeability-regulating polymer membrane as
employed in the dosage units shown in FIG. 1 and FIG. 2 can
10 be selected from a number of polymeric membranes depending
upon the rate of delivery desired and the pharmaceuticals
administered by the dosage unit.

15 The permeability-regulating polymer membranes used are
"non-porous", meaning essentially free of pores. The per-
20 meability-regulating polymer membrane permits the pharma-
ceutical to pass through the membrane along with any skin
permeation-enhancing agent used. It has been found that a
25 suitable non-porous polymer film for use in making the per-
meability-regulating membrane for dosage units having a
number of pharmaceutical components is a (ethylene/vinyl
30 acetate) copolymer film. The vinyl acetate content of the
film is suitably from about 4.5 to about 50 percent by mean
35 weight of the copolymer, presently preferred for many uses
the content is in the range of about 18 to about 40 percent
40 by mean weight. The thickness of the film can also vary.
Generally speaking, the thicker the film used, the slower
45 the rate of transdermal absorption of the pharmaceutical
component present in the reservoir. It has been found that
ordinarily a membrane can be selected from those having a
50 thickness of about 10 to about 100 microns. Ordinarily, a
membrane having a thickness of about 20 to about 80 microns
permits desired transdermal absorption and adequate
55 strength. Other polymeric films can also be used so long as
they are non-porous, bioacceptable, permit the pharmaceuti-

5 cal component to be transdermally absorbed at a desired rate
and have adequate dimensional strength.

10 The reservoir medium employed to dissolve the pharma-
ceutical component in either a macroreservoir or microreser-
15 voirs can vary widely. It is desired that the reservoir
medium can be prepared from a combination of two miscible
co-solvents. It has been found that certain combinations of
20 ethanol and water work well to provide high rates of trans-
dermal absorption, which are constant, and give variability
25 in the absorption rates. For example, if the pharmaceutical
component has one or two hormonal steroids, for example,
estradiol and a progestin, such as levonorgestrel, certain
30 combinations of ethanol and water can be used as the reser-
voir medium to provide desirable constant rates of transder-
mal absorption over a period of 24 hours or longer and
35 variability in the rates of absorption. It has been found
that the combination of ethanol and water having about 55 to
40 85 percent ethanol content, preferably about 60 to about 80
percent, and more preferably about 70 percent ethanol pro-
45 vide maximal rate of transdermal absorption. Combinations
of other solvents can also be used so long as they provide
the desired results.

50 It has also been found desirable to use a C₃-C₄ alkane
diol as the reservoir solvent. Preferred diol compounds
55 useful in the compositions of the present invention include
1,2-propanediol, 1,3-propanediol, 1,2-butanediol, 1,3-

5 butanediol, 1,4-butanediol, or mixtures of these diol compounds. In compositions of the present invention, 1,2-propanediol and 1,2-butanediol are more preferred diol compounds; 1,2-propanediol is an especially preferred diol compound.

15 If one of the C₃-C₄ alkane diols is selected for use as a reservoir solvent, the amount used will vary depending upon the pharmaceutical component and other agents present. Ordinarily, an amount of at least about 20 percent by weight of the solvent is used. Preferably, in making many dosage units, an amount of about 30 to about 90 percent is suitable, if, for example, 1,2-propanediol is used.

30 It is also desirable to use in combination with the miscible co-solvents by incorporating other agents, such as transdermal absorption-enhancing agents. It has been found suitable to use in combination with the combination of ethanol and water, an amount of a long chain alkanolic acid, such as oleic acid, or long-chain alcohol having, for example, decyl or lauryl alcohol. It has been also found useful to have present an effective amount of a lower alkyl ester of lactic acid such as ethyl lactate. Also, it has been found useful to have present an amount of agents sold under the designation Ceraphil, for example, Ceraphil 31 which has lauryl and myristyl lactate ester and lauryl and myristyl alcohol components.

5 A suitable reservoir solution has been found to have
the following weight ratio: Ceraphil 31, n-decyl alcohol,
10 ethyl lactate and propylene alcohol, 1:1:1:2.

 If two pharmaceuticals are present in a reservoir,
either of the macroreservoir or microreservoir type, at
15 least one of the pharmaceuticals should be present in less
than saturated amount in order that the absorption rate
20 ratios of the two pharmaceuticals can be varied and also be
maintained at a constant rate ratio.

 Aqueous gels of organic polymers which are bioaccept-
25 able and compatible with other components of a pharmaceuti-
cal-containing reservoir can be used to convert the reser-
30 voir medium to a semi-solid state. For example, a small
amount of such aqueous gels as gelatin, agar, pectin, methyl
cellulose and polyethylene glycols, hydroxypropyl cellulose,
35 and polyvinyl pyrrolidone can be used. Ordinarily, a small
amount of aqueous gels is adequate to provide the desired
40 increase in viscosity or semi-solid state, for example, 1 to
4 percent in the use of pectin or agar.

 If it is desired that the pharmaceutical in a reservoir
45 is present as microreservoirs, the microreservoirs can be
formed by dissolving the pharmaceutical component in a
50 desired reservoir medium, which is not a solvent for the
polymeric material desired to be used in making the micro-
reservoirs. A number of polymers are suitable, for example,
55 a number of adhesive polymers can be used, for example, a

5 number of polyacrylate-based adhesive polymers, silicone elastomers, polyisobutylene, and the like.

10 The polymeric material selected must permit the pharmaceutical to be released for the desired transdermal absorption and not substantially affect the pharmaceutical component or the permeability-regulating membrane or other components. The reservoir medium containing dissolved/dispersed
15 pharmaceutical and the polymeric material are combined in a suitable amount and agitated using suitable stirring or dispersing means to cause microreservoirs to be formed and
20 homogeneously dispersed in the polymeric material. It is normally desired that the microreservoirs be of a micronic diameter, such as 2 to about 200 microns, usually preferably
25 about 5 to about 100 microns in diameter.

35 The adhesive polymers used in forming the adhesive element can be selected from known adhesives which are bio-acceptable and pressure-sensitive. It is suitable that the
40 adhesive element be in the form of a ring peripheral to a central reservoir, if that is the type of dosage unit of the invention used. Known polyacrylate, polyisobutylene, silicone or the like adhesive polymers can be used. If a peripheral ring is made of such adhesive polymer, it can contain
45 a pharmaceutical which is different from the pharmaceutical component of the central reservoir. The pharmaceutical from the peripheral ring can be present as microreservoirs or can
50 be present in matrix polymer form wherein the pharmaceutical is microdispersed in the adhesive polymer.
55

5

The dosage units can vary in surface area as desired. Generally, they do not exceed about 100 sq cm in area, suitably about 5 to about 80 sq cm, preferably about 10 to about 40 sq cm, generally about 5 to about 50 sq cm being a more preferable size. The dosage units can vary in shape as desired, such as circular, square, rectangular or other desired shape.

20

The dosage units can be, as stated above, multi-regional wherein at least one pharmaceutical is present in one or more regions. The pharmaceuticals in such multi-regional dosage units of this invention are transdermally absorbed therefrom. The multi-regions can be in a form of a central core, with one or more concentric circular bands surrounding the core, in a form of adjacent rectangular regions, or other suitable arrangements of the multi-regions.

25

30

35

40

The multi-regions can have the same or different pharmaceuticals to provide transdermal absorption thereof. The multi-regions can be in the form wherein the pharmaceutical is present in a macroreservoir covered with only a permeability-regulating polymer membrane, in a form wherein the pharmaceutical is in the form of microreservoirs wherein the region is covered or not covered with a permeability-regulating membrane, or one or more of the regions are in the form of a pharmaceutical-dispersing polymer matrix disc. It is preferred that at least one region of a multi-regional

45

50

55

5 dosage unit of this invention be a macroreservoir covered
with a permeability-regulating polymer membrane and provide
10 a constant rate for at least 24 hours and the rate can be
varied as desired.

15 A wide range of pharmaceuticals can be administered by
the dosage units of this invention, so long as they are
capable of being administered transdermally. It has been
20 found that the dosage units are especially useful in admin-
istering two pharmaceuticals from a reservoir covered with a
permeability-regulating membrane wherein at least one phar-
25 maceutical is contained in a reservoir medium in less than a
saturated condition. Thereby, the pharmaceutical can be
30 provided in a constant rate ratio for an extended number of
hours, for example, at least a 24-hour period. Such dosage
unit of this invention is especially useful in providing a
35 combination of estrogenic and progestational steroids for
either fertility regulation or estrogen replacement therapy.
40 The reservoir medium can be modified to provide a variable
rate of one or both of the steroids (or other pharmaceuti-
cals) and the corresponding absorption rate ratios.

45 With regard to estrogenic steroids, 17-beta-estradiol
is a natural and a preferred estrogen. Derivatives of 17-
50 beta-estradiol which are biocompatible, capable of being
absorbed transdermally and preferably bioconvertible to 17-
55 beta-estradiol can also be used, if the amount of absorption
meets the required daily dose of the estrogen component and
if the steroid components are compatible. Such derivatives

5 of estradiol can be selected from esters, either mono- or
10 di-esters. The monoesters can be either 3- or 17-esters.
The estradiol esters can be, illustratively speaking, estro-
diol-3,17-diacetate; estradiol-3-acetate; estradiol-17-ace-
15 tate; estradiol-3,17-divalerate; estradiol-3-valerate;
estradiol-17-valerate; 3-mono, 17 mono- and 3,17-dipivalate
esters; 3-mono, 17-mono and 3,17-dipropionate esters; cor-
20 responding cypionate, heptanoate, benzoate and the like
esters; ethinyl estradiol; estrone; estriol; and other
25 estrogenic steroids and derivatives thereof which are trans-
dermally absorbable, including benzestrol, chlorotrianisene,
dienestrol, mestranol, and the like.

30 The progestational steroids can be selected from
norethindrone, norgestimate, levonorgestrel (or norgestrel
35 containing both levonorgestrel and its (+) enantiomer),
norethynodrel, dydrogesterone, ethynodiol diacetate, deso-
gestrel, 3-keto-desogestrel, hydroxyprogesterone caproate,
40 medroxyprogesterone acetate, norethindrone, norethindrone
acetate, norgestrel, progesterone, and the like.

45 Steroids which are androgenic can also be used in
making the dosage units of this invention such as testos-
terone and its esters, such as testosterone enanthate, 17-
50 alpha-methyl testosterone, 19-nortestosterone and its
esters, such as nandrolone decanoate and the like.

5 Transdermal delivery of testosterone and/or 17-alpha-methyl testosterone could be used in the treatment of hypo-
10 gonadism or used as male contraceptive. When delivered in combination with an estrogen, such as 17-beta-estradiol, from the biregional patch, it could minimize the side
15 effects of delivering androgen alone. These side effects include: muscular overdevelopment, weight gain, acne and increase in libido.
20

Transdermal delivery of medroxy progesterone acetate
25 (MPA) can be used in the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance. When delivered in combination with an estrogen, such as 17-beta-estradiol, from the biregional patch, it could minimize
30 the side effects encountered by taking oral MPA (Provera, by Upjohn). These side effects include breakthrough bleeding, spotting, edema, change in menstrual flow, change in weight,
35 acne, rash and insomnia, etc.

40 The ratios and the amounts of the estrogens and progestins to be administered on a daily basis are known to those skilled in the art. Reference is made, for example, to U.S.
45 Patent No. 5,023,084.

Other pharmaceuticals, either alone or in combination,
50 can be selected for use in carrying out this invention and can be selected from the following: alpha-[1(methylamino)-ethyl]-benzene methanol, which is useful as an adrenergic
55 (bronchodilator); buprenorphine, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide, useful as a narcotic

5

10

15

20

25

30

35

40

45

50

55

analgesic; furosemide and 6-chloro-3, 4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, useful as diuretics; and 2-diphenylmethoxy-N, N-dimethylethanamine, useful as an antihistamine. Other useful drugs include: anti-HIV drugs, such as dideoxy nucleoside; antimicrobial agents, such as penicillins, cephalosporins, tetracycline, oxytetracycline, chlortetracycline, chloramphenicol and sulfonamides; sedatives and hypnotics, such as pentabarbital, sodium pentabarbital, secobarbital sodium, codeine, (a-bromoisovaleryl) urea, and carbromal; psychic energizers, such as 3-(2-aminopropyl) indole acetate and 3-(2-aminobutyl indole acetate; tranquilizers, such as diazepam, chlordiazepoxide hydrochloride, reserpine, chlorpromazine hydrochloride, and thiopropazate hydrochloride; hormones, such as adrenocorticosteroids, for example, 6-methyl-prednisolone; androgenic steroids, for example, testosterone, methyltestosterone, and fluoxymesterone; estrogenic steroids, for example, estrone, estradiol and ethinyl estradiol; progestational steroids, for example, levonorgestrel, progesteron, 17a-hydroxyprogesterone and acetate, medroxyprogesterone and acetate, 19-norprogesterone, and norethindrone; thyroxine; antipyretics, such as aspirin, salicylamide, methylsalicylate, triethanolamine salicylate; morphine and other narcotic analgesics; hypoglycemic agents, for example, sulfonyl ureas such as glypizide, glyburide and chlorpropamide and insulin; antispasmodics, such as atropine, methscopolamine

5 bromide, methscopolamine bromide with phenobarbital, anti-
 malarials, such as the 4-aminoquinolines, 9-aminoquinolines,
10 and pyrimethamine; adrenergic block agents, such as meto-
 prolo; antiarthritic agents, such as sulindac; nonsteroidal
15 anti-inflammatory agents, such as ibuprofen and naproxen;
 vasodilators, such as dipyridamole, isosorbide dinitrate;
 antihypertension agents, such as propanolol, methyldopa and
20 prazosin; contraceptive agents, such as levo-
 norgestrel/estradiol combination and norethindrone acetate
 combination; agents for treating duodenal ulcers, such as
25 cimetidine; and nutritional agents, such as vitamins, essen-
 tial amino acids, and essential fats. The above listing of
30 pharmaceuticals is merely exemplary of the transdermally
 applicable pharmaceuticals. It is contemplated that any
35 pharmaceutical can be utilized may be transdermally adminis-
 tered by use of this invention.

 The presence of enhancing agents in the dosage units
40 together with the pharmaceutical is often highly useful. It
 has been found that the presence of oleic acid as an
 enhancing agent in certain dosage units of this invention is
45 highly advantageous. Other enhancing agents which are use-
 ful in this invention can be selected from the following:
50 long-chain alkanols, long-chain alkanolic acids and their
 esters, ceramide, dialkyl sulfoxide, surfactants, and the
55 like.

5

Example 1

10

15

20

25

30

35

40

45

50

55

A dosage unit as shown in FIG. 1 is fabricated. The backing layer employed is the following. The permeability-regulating polymer membrane used is EVA, 28 percent vinyl acetate, sold by 3M Co., 50 micron thick. The skin permeation rate of levonorgestrel is controlled by using the combination of ethanol and water with varying concentration or ratio as the dissolving solvent for levonorgestrel to form solution which is placed within the reservoir as shown in FIG. 1 as drug reservoir compartment. As shown in FIG. 3, the cumulative levonorgestrel amount of permeation ($\text{mcg}/\text{cm}^2 \pm \text{SEM}$) is varied greatly by varying the ratio of ethanol:water. It is shown that very little permeation is realized when 100 percent water is utilized as well as very low permeation is achieved with 100 percent ethanol. It is noted from the graphs of FIGS. 3A and 3B that greatly enhanced rates of permeation are realized at a ratio of ethanol:water of 60:40 and a ratio of 80:20 and 70:30. It is noted that of the ratios shown, the highest cumulative levonorgestrel permeation rate is realized by utilizing the 70:30 ratio. The data with respect to the difference in the skin permeation of levonorgestrel as a function of the ethanol:water ratio are shown on the graph of FIG. 4 wherein the skin permeation rate of levonorgestrel in $\text{mcg}/\text{cm}^2/\text{hr.} \pm \text{S.D.}$ vs. ethanol:water ratio on a volume/volume basis is shown.

The following table shows the dependence of the skin permeation rate of levonorgestrel and enhancement based on the ethanol:water ratio in the reservoir solution used which contains the levonorgestrel.

Dependence of the Skin Permeation Rate
of Levonorgestrel and Enhancement on the
Volume Fraction of Ethanol in Reservoir Solution

<u>Reservoir Solution</u> ⁽¹⁾ (%V/V)		<u>Skin Permeation Rate</u> ⁽²⁾ (mcg/cm ² /hr \pm S.D.)		<u>Enhancement</u> ⁽³⁾ <u>Factor</u>
<u>Ethanol</u>	<u>Water</u>			
0	100	0.03	(0.01)	1.0
20	80	0.09	(0.03)	3.0
40	60	0.47	(0.02)	15.7
60	40	2.40	(0.68)	80.0
70	30	7.69	(0.94)	256.3
80	20	4.01	(0.33)	133.7
100	0	1.33	(0.55)	44.3

(1) Saturated levonorgestrel solution

(2) Dorsal skin (n = 3 each) freshly excised from hairless rat.

(3) Compared to the skin permeation rate of levonorgestrel from reservoir solution having 100% (V/V) of water as the vehicle.

FIG. 5 shows the difference in the levonorgestrel permeation rate depending upon the content of vinyl acetate in the permeability-regulating polymer membrane as shown in FIG. 1 as permeability-regulating polymer membrane. It is shown that as the weight fraction of vinyl acetate in the

5 permeability-controlling membrane increases from 9 percent
10 to 40 percent, the levonorgestrel permeation rate increases.

15 The particular permeability-regulating membrane utilized in this experiment is an (ethylene/vinyl acetate) copolymer as shown in FIG. 6. The rates of transdermal permeation (in $\text{mcg}/\text{cm}^2/\text{hr} \pm \text{S.D.}$) of levonorgestrel in the
20 hairless rat skin test utilizing a 50 micron (ethylene/vinyl acetate) copolymer membrane having variation in the weight fractions of vinyl acetate from 9% to 40% from a saturated
25 levonorgestrel donor solution containing the ratio of ethanol:water of 70:30.

30 FIG. 7 shows the difference in cumulative levonorgestrel permeation vs. thickness of the permeability-regulating (ethylene/vinyl acetate) copolymer membrane shown in FIG. 1,
35 along with a comparison with the rate of permeation wherein no membrane is utilized, i.e., skin alone. A saturated levonorgestrel solution of ethanol:water of 70:30 on a V/V
40 basis. Two percent of oleic acid was utilized. The membrane polymer contained 28% vinyl acetate. It is noted that differences in the thickness of membrane varied from 30
45 microns to 50 microns and 100 microns. It is noted that substantially more levonorgestrel was absorbed transdermally
50 when a 30 micron membrane was utilized and that the lowest level of permeation was observed when the 100 micron membrane was used.
55

5 FIG. 8 shows the relationship of the permeation rate of
10 levonorgestrel across the permeability-regulating polymer
 membrane utilizing a (ethylene/vinyl acetate) membrane con-
 taining 28 percent vinyl acetate and the reservoir solution
15 containing 70% ethanol and 2% oleic acid and the remainder
 being water. It shows that a higher rate of permeation is
20 obtained utilizing the 30 micron thickness and that a higher
 rate was obtained using a 50 micron thickness than was
 obtained with the 100 micron thickness.

25 FIG. 9 shows the rate of skin permeation of levonorges-
 trel (in $\text{mcg}/\text{cm}^2/\text{hr} \pm \text{S.D.}$) from a reservoir solution having
 varying ratios of ethanol:water on a V/V basis. Reservoir
30 solution contains 5 percent of either azone or 5 percent
 oleic acid as an enhancer as compared to a reservoir solu-
 tion containing neither of the enhancing agents. In each
35 case it is shown that the best skin permeation rate is
 obtained in the range of 60 to 80 percent ethanol. When
40 utilizing 100 percent ethanol with no enhancing agent, about
 2 mcg of levonorgestrel has been administered per hour per
45 cm^2 .

50 FIG. 10 shows the change in permeation rate (on a
 $\text{mcg}/\text{cm}^2/\text{hr}$ basis) from a saturated levonorgestrel reservoir
 solution having a ratio of ethanol:water of 70:30 utilizing
 a permeability-regulating membrane as shown in FIG. 1 where-
55 in the vinylacetate content is 28% and the thickness is 50
 microns. The rate of transdermal absorption is shown vs.
 the concentration of oleic acid as the enhancing agent.

5

10

15

20

25

30

FIG. 11 shows the effect of estradiol loading dose on the permeation rates of levonorgestrel and estradiol across a permeability-regulating (ethylene/vinyl acetate) membrane wherein the vinyl acetate content is 28% and the thickness thereof is 50 microns. Utilized in this evaluation was the hairless rat skin test as described above. The reservoir solution was a saturated levonorgestrel solution wherein the ethanol concentration is 70% and the concentration of oleic acid as the enhancing agent is 2%. Permeation rates (on the basis of $\text{mcg}/\text{cm}^2/\text{hr}$) are shown for estradiol and levonorgestrel. In the graph, the loading dose of estradiol is varied from one to 15 milligrams/milliliter in the reservoir solution.

35

40

45

50

55

FIG. 12 is a curve showing the ratio of the cumulative transdermal absorption of levonorgestrel over the cumulative transdermal absorption of estradiol. The data in the graph show that as the loading dose of estradiol is increased, the permeation rate ratio of levonorgestrel over estradiol varies from greater than unity to less than unity. The permeation rate ratio of levonorgestrel over estradiol utilizing a 2 milligram/milliliter loading of estradiol is about 6.5 and at 5 milligram/milliliter loading of estradiol, the permeation rate ratio of levonorgestrel over estradiol is reduced to about 1 and is further reduced to about 0.2 at an estradiol loading of 15 milligrams/milliliter.

FIG. 13 shows the cumulative estradiol permeation (based on $\text{mcg}/\text{cm}^2/\text{hr} \pm \text{S.D.}$) utilizing a dosage unit such as that shown in FIG. 1 utilizing human cadaver skin test procedure. The transdermal absorption of estradiol is from a reservoir solution saturated with levonorgestrel. Various estradiol concentrations are utilized in the comparative testing, varying from an estradiol loading which is a saturated solution to 10, 5, 2, 1 and 0.2 milligrams/milliliter of estradiol loading. Utilizing a dosage unit such as that shown in FIG. 1, cumulative levonorgestrel permeation (based on $\text{mcg}/\text{cm}^2 \pm \text{S.D.}$) is shown. A permeation profile of levonorgestrel across a permeability-regulating membrane which is an (ethylene/vinyl acetate) membrane containing 28 percent vinyl acetate and utilizing human cadaver test procedure.

FIG. 14 shows a permeation profile of levonorgestrel across an (ethylene/vinyl acetate) membrane-covered human cadaver skin. Various estradiol loadings are used in the reservoir solution varying from 0.2 mg/ml to saturation.

FIG. 15 shows a dosage unit as shown in FIG. 1 wherein the reservoir solution has varying levels of estradiol loading and the permeation rates of levonorgestrel and estradiol have been varied depending upon estradiol loading. A permeability-regulating (ethylene/vinyl acetate) membrane is utilized as the permeation-controlling membrane shown in FIG. 1. The human cadaver skin test was utilized. The data show the change in the permeation rates (based upon

5 mcg/cm²/hr \pm S.D.) of both estradiol and levonorgestrel from
a reservoir solution consisting of saturated levonorgestrel
10 with a ratio of ethanol:water at 70:28 by volume. The
reservoir solution also contains 2% of oleic acid. The
15 permeability-regulating membrane used comprises 28% vinyl
acetate and has a thickness of 50 microns. The estradiol
loading varies from zero to 15 milligrams/milliliter. It is
20 shown that the permeation rate for levonorgestrel at zero
percent estradiol loading in this system is about 1 and
25 slightly declines to about 0.7 mcg/cm²/hr at 15 milli-
grams/milliliter of estradiol.

30 FIG. 16 shows a graph wherein the effect of estradiol
loading on permeation rate ratio of levonorgestrel over
estradiol. The graph shows that the permeation rate ratio
35 is greatly reduced depending upon the loading dose of estra-
diol. The permeability-regulating (ethylene/vinyl acetate)
membrane utilized has 28 percent vinyl acetate and has a
40 thickness of 50 microns. The reservoir solution, which is
saturated with levonorgestrel, has 70 percent ethanol and 2
45 percent oleic acid content. The human cadaver skin test is
utilized.

50 FIG. 17 is a graph showing the effect of drug releasing
area on dosage rate ratio of levonorgestrel over estradiol.
A dosage unit of the type shown in FIG. 2 is utilized. The
55 reservoir solution in drug-reservoir compartment A is a
saturated levonorgestrel solution wherein the ethanol:water

5 has a ratio of 70:30 and the permeation rate of levonorges-
trel is 21.84 mcg/cm²/day. The permeability-regulating
10 membrane is an (ethylene/vinylacetate) membrane containing
28 percent vinyl acetate and having a thickness of 50
15 microns. The permeation rate of estradiol in the polyacry-
late adhesive used to make the peripheral ring as shown as
drug-reservoir compartment B in the FIG. 2 dosage unit is
20 24.36 mcg/cm²/day. As the area of the pharmaceutical-
releasing area pertaining to levonorgestrel is increased
25 over the pharmaceutical-releasing area of estradiol, the
ratio of daily dosage rate of levonorgestrel over the daily
dosage rate of estradiol is increased. It is shown, for
30 example, that the ratio of the daily dosage rate of levonor-
gestrel/daily dosage rate of estradiol changes from about 2
when the ratio of the pharmaceutical-releasing area of levo-
35 norgestrel/pharmaceutical-releasing area of estradiol is 2
to about a daily dosage rate of levonorgestrel/daily dosage
40 rate of estradiol of about 7.5 when the permeability-
releasing area of levonorgestrel/pharmaceutical-releasing
45 area of estradiol is 8. The following table compares the
skin permeation rates of estradiol and levonorgestrel across
permeability-regulating membranes of different compositions
50 when utilized in the human cadaver skin test.

Comparison Between Skin Permeation Rates of Estradiol
and Levonorgestrel Across Various Polymeric Membranes
Applied on Human Cadaver Skin⁽¹⁾

<u>Membrane</u>	<u>Thickness</u> (micron)	<u>Permeation Rate⁽²⁾</u> (mcg/cm ² hr \pm S.D.)	
		<u>Estradiol</u>	<u>Levonorgestrel</u>
(Ethylene/vinyl acetate) Copolymer ⁽³⁾	51	0.17 (0.02)	0.64 (0.16)
Polyethylene ⁽⁴⁾	51	0.93 (0.18)	3.01 (0.58)
Silicone	300	0.00	0.17 (0.02)

(1) Human cadaver skin (female, 34 years old; thigh region) covered with polymeric membrane.

(2) From a saturated solution of levonorgestrel, in 70% ethanol and 2% oleic acid, which contains 0.5 mg/ml of estradiol.

(3) 3M Co. (VAc, 28% W/W); 51 micron)

(4) 3M Co. (microporous, 18 micron; void volume, 78%)

Example 2

A bi-regional transdermal drug delivery system which can simultaneously deliver a progestin, such as levonorgestrel (LNG) and an estrogen, such as 17-beta-estradiol (E2) from its central and peripheral regions, respectively, is fabricated by using the following processes and equipment:

Thoroughly mix 0.52 part of E2, 10.81 parts of oleic acid (OA) and 88.67 parts of polyacrylate adhesive solution (Duro-Tak 80-1054, by National Starch and Chemical Co., New Jersey, which contains 36% of solid) by weight in a container to form a homogeneous E2/OA adhesive solution. This

5

10

15

20

25

30

35

40

45

50

55

solution is coated onto a silicone-coated release liner (Akrosil B2M) by a specially-designed pattern coating device to form a circular ring of peripheral region. This peripheral region has an inner and outer radius of 1.59 cm and 2.18 cm, respectively, which gives a 0.59 cm width and 7 sq cm to the area of the region. The wet thickness of the coating of this adhesive solution is controlled at 500 microns which is then cured in an oven at 60°C for 10 minutes to form the dried matrix of peripheral region about 200 microns thickness. The peripheral region obtained by this fabrication process is thereafter named Intermediate Product A (IP-A).

Oleic acid, ethanol and water are mixed thoroughly at the weight ratio of 1:37:14 to form a homogeneous hydro-alcoholic solution system (HASS). An amount of 0.0036 part by weight of LNG is dissolved in 1.000 part by weight of HASS to form a homogeneous LNG/HASS solution. An amount of 400 microliters of LNG/HASS solution is carefully applied by a dispenser onto a piece of 50 micron-thick heat-sealable (ethylene/vinyl acetate) membrane (EVA, 28% vinyl acetate, by 3M Co.) which was precast on the siliconized paper release liner. The dispensed LNG/HASS solution is quickly covered with a piece of drug-impermeable/heat-sealable backing film (Scotch Pak 1109 by 3M Co.). The central region of this biregional drug delivery system is then formed by thermally sealing the backing film to the EVA film by a spe-

5 cially-designed heat seal machine. Sealing process is per-
formed at 370°F and 50 psi for 1 (one) second of dwell time.
10 The central region (7 sq cm in size) obtained by this
process is designated Intermediate Product B (IP-B).

15 To complete the fabrication of the biregional transder-
mal drug delivery system, IP-A is carefully laminated on the
IP-B by a laminating device. The final product (15 sq cm in
20 size), which is in the form of a transdermal patch, can be
cut out by a die cutter.

25 The novel design of this patch product will allow the
two drugs to be delivered simultaneously from a single unit
of transdermal patch. LNG is delivered from the central
30 region, while E2 is delivered from the peripheral region.
In addition to changing the formulation ingredients in each
region, the daily delivery rate of each drug can be altered
35 by changing the relative size of the surface area of the two
regions. This final product has the equal size of surface
40 area (7 cm. sq) for the central and peripheral regions to
allow desired amount of LNG and E2, respectively, to be
delivered. In the in-vitro skin permeation study, this
45 final product is found to give permeation rate of 0.62 and
0.30 mcg/sq cm/hr of LNG and E2, respectively, which can be
50 translated into the daily delivery rate of 104.2 mcg of LNG
and 50.4 mcg of E2.

5

Example 3

10

A bi-regional transdermal drug delivery system, which can simultaneously deliver a combined dosage of progestin, such as levonorgestrel (LNG), and estrogen, such as 17-beta-estradiol (E2), from its central region, is fabricated by using the following processes and equipment:

15

20

Thoroughly mix 5.06 parts of Ceraphil 31 (by Van Dyk/New Jersey), 94.94 parts of polyacrylate adhesive solution (Duro-Tak 80-1054, by National Starch and Chemical Co./New Jersey, which contains 48% of solid) by weight in a container to form a homogeneous adhesive solution. This solution is coated onto a silicone-coated release liner (Akrosil B2M) by a specially-designed pattern coating device to form a circular ring of peripheral region. This peripheral region has an inner and outer radius of 1.59 cm and 2.18 cm, respectively, which gives 0.59 cm to the width and 7 sq cm to the area of the region. The wet thickness of the coating of this adhesive solution is controlled at 500 microns which is then cured in an oven at 60°C for 10 minutes to form the dried matrix of peripheral region about 220 microns thick. The peripheral region obtained by this process is designated Intermediate Product A (IP-A).

25

30

35

40

45

50

55

Oleic acid, ethanol and water are mixed thoroughly at the weight ratio of 1:37:14 to form a homogeneous hydro-alcoholic solvent system (HASS). An amount of 0.0010 part by weight of E2 and 0.0036 part by weight of LNG are dissolved in 1.000 part by weight of HASS to form a homogeneous

5 E2/LNG/HASS solution. An amount of 400 microliters of
10 E2/LNG/HASS solution is carefully applied by a dispenser
onto a piece of 50 micron-thick heat-sealable (ethylene/
vinyl acetate) membrane (EVA, 28% vinyl acetate, by 3M Co.)
15 which was precast on the siliconized paper release liner.
The dispensed E2/LNG/HASS solution is quickly covered with a
20 piece of drug-impermeable/heat-sealable backing film (Scotch
Pak 1109 by 3M Co.). The central region of this biregional
drug delivery system is then formed by thermally sealing the
25 backing film to the EVA film by a specially-designed heat
seal machine. The sealing process is performed at 370°F and
30 50 psi for 1 (one) second of dwell time. The central region
(7 sq cm in size) obtained by this process is designated
Intermediate Product B (IP-B).

35 To complete the fabrication of the biregional transder-
mal drug delivery system, IP-A is carefully laminated onto
40 the IP-B by a laminating device. The final product (15 sq
cm in size), which is in the form of a transdermal patch, is
cut out by a die cutter.

45 The novel design of this patch product will allow the
two drugs to be delivered simultaneously from a single
transdermal patch. Both E2 and LNG are delivered from the
50 central region of this biregional transdermal patch. The
peripheral region, which is made up of a pressure sensitive
55 adhesive that contains a water-repelling tackifier (Ceraphil
31) composition: lauryl lactate 50-60 percent, myristyl

5 lactate 15-20 percent, lauryl alcohol 10-20 percent,
myristyl alcohol 2-10 percent will ensure the central region
10 to have good contact with skin. In addition to varying the
thickness and/or the vinyl acetate content of the EVA mem-
brane, the daily delivery rate of each drug can be altered
15 by changing their concentration in the HASS that is sealed
in the central region. This dosage unit has the equal size
20 of surface area (7 sq cm) for the central and peripheral
regions to allow desired doses of LNG and E2 to be
delivered. In the in-vitro skin permeation study, this
25 final product was found to give permeation rate of 0.62 and
0.26 mcg/sq cm/hr of LNG and E2, respectively, which can be
30 translated into the daily delivery rate of 104.2 mcg of LNG
and 43.7 mcg of E2. Another dosage unit formulation in
35 which the central region is made up of 0.005 part by weight
of E2 and 0.001 part by weight of LNG in 1.000 part by
weight of HASS, is found to give human cadavers kin permea-
40 tion rate of 1.63 and 0.25 mcg/sq cm/hr, respectively, in an
in vitro test. These skin permeation rates of E2 and LNG
45 can be translated into daily delivery rate of 273.8 and 42.0
mcg/day, respectively.

50 Example 4

A bi-regional transdermal drug delivery system which
can simultaneously deliver a progestin, such as levonorges-
55 trel (LNG), and an estrogen, such as 17-beta-estradiol (E2),

5 from its central and peripheral region, respectively, is fabricated by using the following processes and equipment:

10 Thoroughly mix 0.48 part of E2, 9.68 parts of oleic acid (OA) and 89.84 parts of polyacrylate adhesive solution (Duro-Tak 80-1054, by National Starch and Chemical Co., New
15 Jersey, which contains 36% of solid) by weight in a container to form a homogeneous E2/OA adhesive solution. This solution is coated onto a silicone-coated release liner (Akrosil B2M) by a specially-designed pattern coating device
20 to form a circular ring of peripheral region. This peripheral region has an inner and outer radius of 0.9 cm and 1.78 cm, respectively, which provides a 0.88 cm width and 7.46 sq cm area of the region. The wet thickness of the coating of this adhesive solution is controlled at 500
25 microns which is then cured in an oven at 60°C for 10 minutes to form the dried matrix of peripheral region of about 200 microns thick. The peripheral region obtained by this product is designated Intermediate Product A (IP-A).
30
35
40

45 Ceraphil 31 (by Van Dyk/New Jersey), n-decyl alcohol, dimethyl sulfoxide and ethanol are mixed thoroughly at the weight ratio of 1:1:1:2 to form a homogeneous alcoholic enhancer system (AES). Dissolve excess of LNG in AES to
50 form an oversaturated LNG/AES solution. Carefully dispense 130 microliter of LNG/AES solution by a dispenser onto a piece of 50 micron-thick heat-sealable (ethylene/vinyl acetate) membrane (EVA, 28% vinyl acetate, by 3M Co.) which was
55 precast on the siliconized paper release liner. The dis-

5
10
15
20
25
30
35
40
45
50
55

pensed LNG/AES solution is quickly covered with a piece of drug-impermeable/heat-sealable backing film (Scotch Pak 1109 by 3M Co.). The central region of this biregional drug delivery system is then formed by thermally sealing the backing film to the EVA film by a specially-designed heat seal machine. The sealing process is performed at 370°F and 50 psi for 1 (one) second of dwell time. The central region (2.01 sq cm in size) obtained by this process is designated Intermediate Product B (IP-B).

To complete the fabrication of the biregional transdermal drug delivery system, IP-A is carefully laminated on the IP-B by a specially-designed laminating device. The final dosage unit (10 sq cm in size) is cut out by a die cutter.

The novel design of this patch product will allow the two drugs to be delivered simultaneously from a single transdermal dosage unit. LNG is delivered from the central region, while E2 is delivered from the peripheral region. In addition to variation of the formulation ingredients in each region, the daily delivery rate of each drug can be altered by varying the relative size of the surface area of the two regions. This final product has the 2.01 and 7.46 sq cm of surface area for the central and peripheral regions, respectively, to allow desired amount of LNG and E2, respectively, to be delivered. In the in-vitro skin permeation study, this final dosage unit is found to give permeation rates of 3.18 and 0.28 mcg/sq cm/hr of LNG and

5 E2, respectively, which can be translated into the daily
delivery rate of 153.3 mcg of LNG and 50.1 mcg of E2.

10 Example 5

15 A bi-regional transdermal drug delivery system which
can simultaneously deliver a progestin, such as levonorges-
trel (LNG), and an estrogen, such as 17-beta-estradiol (E2),
20 from its central and peripheral region, respectively, is
fabricated by using the following processes and equipment:

25 Thoroughly mix 0.48 part of E2, 9.68 parts of oleic
acid (OA) and 89.64 parts of polyacrylate adhesive solution
(Duro-Tak 80-1054, by National Starch and Chemical Co., New
30 Jersey, which contains 36% of solid) by their weight in a
container to form a homogeneous E2/OA adhesive solution.
35 This solution is coated onto a silicone-coated release liner
(Akrosil B2M) by a specially-designed pattern coating device
to form a circular ring of peripheral region. This peri-
40 pheral region has an inner and outer radius of 0.9 cm and
1.78 cm, respectively, which gives a region having a 0.88 cm
width and a 7.46 sq cm area. The wet thickness of the coat-
45 ing of this adhesive solution is controlled at 500 microns
which is then cured in an oven at 60°C for 10 minutes to
50 form the dried matrix of peripheral region about 200 microns
thick. The peripheral region obtained by this product is
55 designated Intermediate Product A (IP-A).

5 Ceraphil 31 (by Van Dyk/New Jersey), n-decyl alcohol,
ethyl lactate and propylene glycol are mixed thoroughly at
10 the weight ratio of 1:1:1:2 to form a homogeneous nonethano-
lic enhancer solvent system (NES). Dissolve excess of LNG
15 in NES to form an oversaturated LNG/NES solution. Carefully
dispense 150 microliter of LNG/NES solution by a dispenser
onto a piece of 50 micron-thick heat-sealable (ethylene/
20 vinyl acetate) membrane (EVA, 28% vinyl acetate, by 3M Co.)
which was precast on the siliconized paper release liner.
Quickly cover the dispensed LNG/NES solution with a piece of
25 drug-impermeable/heat-sealable backing film (Scotch Pak 1109
by 3M Co.). The central region of this biregional drug
30 delivery system is then formed by thermally sealing the
backing film to the EVA film by a specially-designed heat
seal machine. Sealing process was performed at 370°F and 50
35 psi for 1 (one) second of dwell time. The central region
(2.01 sq cm in size) obtained by this process is designated
40 Intermediate Product B (IP-B).

To complete the fabrication of the biregional transder-
45 mal drug delivery system, IP-A is carefully laminated on the
IP-B by a laminating device. The final dosage unit (10 sq
cm in size), is cut out by a die cutter.

50 The novel design of this patch product allows the two
drugs to be delivered simultaneously from a single transder-
mal dosage unit. LNG is delivered from the central region,
55 while E2 is delivered from the peripheral region. In addi-
tion to variation of the formulation ingredients in each

5 region, the daily delivery rate of each drug can be altered
10 by changing the relative size of the surface area of the two
regions. This final dosage unit product has the 2.01 and
15 7.46 sq cm of surface area for the central and peripheral
regions, respectively, to allow desired amount of LNG and
E2, respectively, to be delivered. In the in-vitro skin
20 permeation study, this final dosage unit is found to give
permeation rate of 2.32 and 0.28 mcg/sq cm/hr of LNG and E2,
25 respectively, which can be translated into the daily
delivery rate of 112.0 mcg of LNG and 50.1 mcg of E2.

30 Example 6

A bi-regional transdermal drug delivery system which
can simultaneously deliver a progestin, such as norethin-
35 drone (NET), and an estrogen, such as ethinyl estradiol
(EE), from its central and peripheral regions, respectively,
40 can be fabricated by using the following processes and
equipment:

Thoroughly mix 0.65 part of EE, 8.96 parts of n-decyl
45 alcohol (n-DA) and 90.39 parts of polyacrylate adhesive
solution (Duro-Tak 80-1054, by National Starch and Chemical
50 Co., New Jersey, which contains 36% of solid) by weight in a
container to form a homogeneous EE/n-DA adhesive solution.
This solution is coated onto a silicone-coated release liner
55 (Akrosil B2M) by a specially-designed pattern coating device
to form a circular ring of peripheral region. This peri-

5 peripheral region has an inner and outer radia of 1.956 cm and
2.52 cm, respectively, which gives 0.66 cm to the width and
10 7.93 sq cm to the area of the region. The wet thickness of
the coating of this adhesive solution is controlled at 500
15 microns which is then cured in an oven at 60°C for 10
minutes to form the dried matrix of peripheral region about
200 microns thick. The peripheral region obtained by this
20 product is designated Intermediate Product A (IP-A).

 Ceraphil 31 (by Van Dyk/New Jersey), n-decyl alcohol,
ethyl lactate and propylene glycol are mixed thoroughly at
25 the weight ratio of 1:1:1:2 to form a homogeneous nonethano-
lic enhancer system (NES). Dissolve excess of LNG in NES to
30 form an oversaturated NET/NES solution. Carefully apply 150
microliter of NET/NES solution by a dispenser onto a piece
of 50 micron-thick heat-sealable (ethylene/vinyl acetate)
35 membrane (EVA, 28% vinyl acetate, by 3M Co.), which was
precast on a siliconized paper release liner. Quickly cover
40 the dispensed NET/NES solution with a piece of drug-imper-
meable/heat-sealable backing film (Scotch Pak 1109 by 3M
Co.). The central region of this biregional drug delivery
45 system is then formed by thermally sealing the backing film
to the EVA film by a specially-designed heat seal machine.
50 Sealing process was performed at 370°F and 50 psi for 1
(one) second of dwell time. The central region (12.0 sq cm
in size) obtained by this process is designated Intermediate
55 Product B (IP-B).

5 To complete the fabrication of the biregional transdermal drug delivery system, IP-A is carefully laminated onto
10 the IP-B by a laminating device. The final product (20 sq cm in size), which is in the form of a transdermal patch, is cut out by a die cutter.

15 The novel design of this patch product will allow the two drugs to be delivered simultaneously from a single dosage unit. NET is delivered from the central region which
20 does not contain ethanol as solvent, while EE is delivered from the peripheral region. In addition to changing the
25 formulation ingredients in each region, the daily delivery rate of each drug can be altered by varying the relative size of the surface area of the two regions. This final
30 product has 12.0 and 7.93 sq cm of surface area for the central and peripheral regions, respectively, to allow
35 desired amount of NET and EE, respectively, to be delivered. In the in-vitro skin permeation study, this final product
40 was found to give permeation rate of 2.69 and 0.19 mcg/sq cm/hr of NET and EE, respectively, which can be translated
45 into the daily delivery rate of 774.7 mcg of NET and 36.2 mcg of EE.

50 Example 7

55 A bi-regional transdermal drug delivery system which can simultaneously deliver a progestin, such as medroxy progesterone acetate (MPA), and an estrogen, such as 17-beta-estradiol (E2), from its central and peripheral region,

5
respectively, can be fabricated by using the following
processes and equipment:

10 Thoroughly mix 0.48 part of E2, 9.68 parts of isopropyl
myristate (IPM) and 89.84 parts of polyacrylate adhesive
15 solution (Duro-Tak 80-1054, by National Starch and Chemical
Co., New Jersey, which contains 36% of solid) by their
weight in a container to form a homogeneous E2/IPM adhesive
20 solution. This polyacrylate adhesive has about 5 percent
vinyl acetate polymer unit content. This solution is coated
25 onto a silicone-coated release liner (Akrosil B2M) by a
specially-designed pattern coating device to form a circular
ring of peripheral region. This peripheral region has an
30 inner and outer radia of 2.36 cm and 2.82 cm, respectively,
which gives 0.46 cm to the width and 7.50 sq cm to the area
of the region. The wet thickness of the coating of this
35 adhesive solution is controlled at 500 microns which is then
cured in an oven at 60°C for 10 minutes to form the dried
40 matrix of peripheral region about 200 microns thick. The
peripheral region obtained by this product is designated
45 Intermediate Product A (IP-A).

 Ceraphil 31 (by Van Dyk/New Jersey), n-decyl alcohol,
ethyl lactate and ethanol are mixed thoroughly at the weight
50 ratio of 1:1:1:2 to form a homogeneous alcoholic enhancer
system (AES). Dissolve excess of MPA in AES to form an
oversaturated MPA/AES solution. Carefully dispense 150
55 microliter of MPA/AES solution by a dispenser onto a piece

5 of 50 micron-thick heat-sealable (ethylene/vinyl acetate)
membrane (EVA, 28% vinyl acetate, by 3M Co.) which was pre-
10 cast on the siliconized paper release liner. Quickly cover
the dispensed MPA/AES solution with a piece of drug-imper-
meable/heat-sealable backing film (Scotch Pak 1109 by 3M
15 Co.). The central region of this biregional drug delivery
system is then formed by thermally sealing the backing film
to the EVA film by a specially-designed heat seal machine.
20 Sealing process was performed at 370°F and 50 psi for 1
(one) second of dwell time. The central region (16.0 sq cm
25 in size) obtained by this process is designated Intermediate
Product B (IP-B).

30 To complete the fabrication of the biregional transder-
mal drug delivery system, IP-A is carefully laminated onto
the IP-B by a laminating device. The final product (25.0
35 sq cm in size), which is in the form of a transdermal patch,
can be cut out by a die cutter.

40 The novel design of this patch product will allow the
two drugs to be delivered simultaneously from a single
dosage unit. MPA is delivered from the central region,
45 while E2 is delivered from the peripheral region. In addi-
tion to variation of the formulation ingredients in each
region, the daily delivery rate of each drug can be altered
50 by changing the relative size of the surface area of the two
regions. This final product has the 16.0 and 7.50 sq cm of
55 surface area for the central and peripheral regions, respec-
tively, to allow desired amount of MPA and E2, respectively,

5
10
15
to be delivered. In the in-vitro skin permeation study, this final product was found to give permeation rate of 39.13 and 0.31 mcg/sq cm/hr of MPA and E2, respectively, which can be translated into the daily delivery rate of 15.03 mcg of MPA and 55.8 mcg of E2.

20 Example 8

25 A bi-regional transdermal drug delivery system which can simultaneously deliver two androgens, such as testosterone (T) and 17-alpha-methyl testosterone (m-T) and an estrogen, such as 17-beta-estradiol (E2), from its central and peripheral region, respectively, is fabricated by using the following processes and equipment:

30
35 Thoroughly mix 0.65 part of E2, 8.96 parts of n-decyl alcohol (n-DA) and 90.39 parts of polyacrylate adhesive solution (Duro-Tak 80-1054, by National Starch and Chemical Co., New Jersey, which contains 36% of solid) by their weight in a container to form a homogeneous E2/n-DA adhesive solution. This solution is coated onto a silicone-coated
40
45 release liner (Akrosil B2M) by a specially-designed pattern coating device to form a circular ring of peripheral region. This peripheral region has an inner and outer radii of 1.96 cm and 2.52 cm, respectively, which gives 0.56 cm to the width and 7.93 sq cm to the area of the region. The wet
50
55 thickness of the coating of this adhesive solution is controlled at 500 microns which is then cured in an oven at

5 60°C for 10 minutes to form the dried matrix of peripheral
region about 200 microns thick. The peripheral region
10 obtained by this product is designated Intermediate Product
A (IP-A).

15 Ceraphil 31 (by Van Dyk/New Jersey), n-decyl alcohol,
ethyl lactate and propylene glycol are mixed thoroughly at
the weight ratio of 1:1:1:2 to form a homogeneous nonethano-
20 lic enhancer system (NES). Dissolve excess amounts of T and
m-T in NSS to form an oversaturated T and m-T/NES solution.
25 Carefully dispense 150 microliter of T and m-T/NES solution
by a dispenser onto a piece of 50 micron-thick heat-sealable
(ethylene/vinyl acetate) membrane (EVA, 28% vinyl acetate,
30 by 3M Co.) which was precast on the siliconized paper
release liner. Quickly cover the dispensed T and m-T/NES
solution with a piece of drug-impermeable/heat-sealable
35 backing film (Scotch Pak 1109 by 3M Co.). The central
region of this biregional drug delivery system is then
40 formed by thermally sealing the backing film to the EVA film
by a specially-designed heat seal machine. Sealing process
45 was performed at 370°F and 50 psi for 1 (one) second of
dwell time. The central region (12.0 sq cm in size)
obtained by this process is designated Intermediate Product
50 B (IP-B).

To complete the fabrication of the biregional transder-
55 mal drug delivery system, IP-A is carefully laminated onto
the IP-B by a laminating device. The final product (20 sq

5 cm in size), which is in the form of a transdermal patch, is cut out by a die cutter.

10 The novel design of this patch product will allow the two drugs to be delivered simultaneously from a single dosage unit of transdermal patch. T and m-T are delivered
15 from the central region, while E2 is delivered from the peripheral region. In addition to changing the formulation ingredients in each region, the daily delivery rate of each
20 drug can be altered by modifying the relative size of the surface area of the two regions. This final product has 12.0 and 7.93 sq cm of surface area for the central and peripheral regions, respectively, to allow desired amount of
25 T, m-T and E2, respectively, to be delivered. In the in-vitro skin permeation study, this final dosage unit is found to give permeation rates of 14.34, 13.64 and 0.24 mcg/sq
30 cm/hr of T, m-T and E2, respectively, which can be translated into the daily delivery rate of 4,130.0 mcg of T, 3,928.3 mcg of m-T and 45.7 mcg of E2.

45 Example 9

A bi-regional transdermal drug delivery system which can simultaneously deliver a progestin, such as progesterone
50 (P4), and an estrogen, such as 17-beta-estradiol (E2), from its central and peripheral regions, respectively, can be fabricated by using the following processes and equipment:

55

5 Thoroughly mix 0.48 part of E2, 9.68 parts of isopropyl
myristate (IPM) and 89.84 parts of polyacrylate adhesive
10 solution (Duro-Tak 80-1054, by National Starch and Chemical
Co., New Jersey, which contains 36% of solid) by weight in a
15 container to form a homogeneous E2/IPM adhesive solution.
This solution is coated onto a silicone-coated release liner
(Akrosil B2M) by a specially-designed pattern coating device
20 to form a circular ring of peripheral region. This peri-
pheral region has an inner and outer radia of 2.36 cm and
2.82 cm, respectively, which gives a region having 0.46 cm
25 width and 7.50 sq cm area. The wet thickness of the coating
of this adhesive solution is controlled at 500 microns which
30 is then cured in an oven at 60°C for 10 minutes to form the
dried matrix of peripheral region having a thickness of
about 200 microns. The peripheral region obtained by this
35 product is designated Intermediate Product A (IP-A).

 Ceraphil 31 (by Van Dyk/New Jersey), n-decyl alcohol,
40 ethyl lactate and ethanol are mixed thoroughly at the weight
ratio of 1:1:1:2 to form a homogeneous alcoholic enhancer
system (AES). Dissolve excess amount of P4 in AES to form
45 an oversaturated P4/AES solution. Carefully dispense 150
microliter of P4/AES solution by a dispenser onto a piece of
50 50 micron-thick heat-sealable (ethylene/vinyl acetate) mem-
brane (EVA, 28% vinyl acetate, by 3M Co.) which was precast
on the siliconized paper release liner. Quickly cover the
55 dispensed P4/AES solution with a piece of drug-imper-
meable/heat-sealable backing film (Scotch Pak 1109 by 3M

5 Co.). The central region of this biregional drug delivery
system is then formed by thermally sealing the backing film
10 to the EVA film by a specially designed heat seal machine.
Sealing process was performed at 370°F and 50 psi for 1
15 (one) second of dwell time. The central region (16.0 sq cm
in size) obtained by this process is designated Intermediate
Product B (IP-B).

20 To complete the fabrication of the biregional transder-
mal drug delivery system, IP-A is carefully laminated onto
25 the IP-B by a laminating device. The final dosage unit
product (25.0 sq cm in size), is cut out by a die cutter.

30 The novel design of this dosage unit product allows the
two drugs to be delivered simultaneously. P4 is delivered
from the central region, while E2 is delivered from the
35 peripheral region. In addition to variation of the formula-
tion ingredients in each region, the daily delivery rate of
each drug can be altered by changing the relative size of
40 the surface area of the two regions. This dosage unit has
the 16.0 and 7.50 sq cm of surface area for the central and
45 peripheral regions, respectively, to allow desired amount of
P4 and E2, respectively, to be delivered. In the in-vitro
50 skin permeation study, this final product was found to give
permeation rate of 44.88 and 0.31 mcg/sq cm/hr of P4 and E2,
respectively, which can be translated into the daily
55 delivery rate of 17.23 milligram of P4 and 55.8 mcg of E2.

5
Example 10

10 This example describes multi-region transdermal contra-
ceptive delivery (mr-TCD) dosage units and methods for
making them. The dosage units can be designed to deliver
15 different contraceptive steroid hormones from different
regions within a single dosage unit. Combination of a pro-
gestin and an estrogen can be delivered transdermally from a
20 single dosage unit of this system to achieve desired contra-
ceptive efficacy. The dosage unit has a hormone-containing
layer having different regions in which different steroids
25 with/without skin permeation enhancers are contained. A
region can contain a progestin with enhancer(s) while
another region can contain an estrogen without enhancer(s)
30 or with different enhancer(s). If desired, a mr-TCD system
can have a region which contains no steroid hormones and no
35 skin permeation enhancer and which is used to segregate the
other hormone-containing regions. The location and the area
of each region in a mr-TCD system can vary and can be speci-
40 fically designed to control the release of hormones at opti-
mal rates to achieve greater contraceptive efficacy.

45 Factors that can be varied to control the amount or
ratio of amount of progestin and estrogen from such a system
50 include:

1. Area and area ratio of each region.
2. Hormone concentration in the polymer or polymer adhe-
55 sive which forms each region.

- 5 3. Types of polymer or polymer adhesive which form each
 region.
- 10 4. Types of skin permeation enhancers incorporated in the
 polymer or polymer adhesive.
- 15 5. Amount of skin permeation enhancer(s) incorporated in
 the polymer or polymer adhesive.
- 20 6. Thickness of coating of each region.

FIG. 18 shows a cross sectional view of a dosage unit
and top plan view of a three-region mr-TCD system. This
system consists of the following elements:

- 25 A. Low adhesion hormone-impermeable release liner.
- 30 B. Central-region, which contains hormone with/without
 skin permeation enhancers.
- 35 C. Peripheral-region, which contains hormone with/without
 skin permeation enhancers.
- 40 D. Hormone-impermeable backing layer.
- 45 E. Barrier region which contains no hormones nor skin
 permeation enhancers.

50 The selection of which hormone (estrogen or progestin)
to incorporate into which region (either central or peri-
pheral) depends on therapeutic needs, formulation factors
and fabrication procedures.

55 If skin permeation enhancer is incorporated in the
central region B along with a progestin, an estrogen can be
incorporated in peripheral region C which contains no or

5 very little skin permeation enhancer. By such a configura-
tion, the estrogen-containing peripheral region C can also
10 serve as a peripheral adhesive ring which will help to main-
tain adhesiveness of the whole mr-TCD on the application
15 site of the skin. This configuration is especially useful
in the situation in which the central region B is required
to contain higher concentration of skin permeation enhancer
20 in order to achieve desired skin permeation rate of proges-
tin and thereby loses adequate adhesiveness. Therefore, as
25 a general rule, the region which contains formulation that
is more adhesive to the skin should be assigned as peri-
pheral region.

30 The estrogens that can be used in this system include
17-estradiol, ethinyl estradiol, and others described above.
Progestins, such as levonorgestrel, norethindrone, and
35 others described above, can be used with the estrogen used.
Skin permeation enhancers of various types as described
40 above, surfactants (anionic, cationic, non-ionic and
zwitterionic types), and the combination of surfactants with
straight long-chain alkanols, alkanolic acids or alkanolic
45 acid esters, can be used in various concentrations in the
central region of the mr-TCD system. Region E can be left
50 as a trench or be filled with a material, such as a polymer
or polymer adhesive, to prevent or to inhibit the inter-
regional migration of hormones and/or skin permeation
55 enhancers. The polymers used to construct this band can be
selected from high-density polyethylene, polypropylene,

5 polystyrene, polyisobutylene, and other suitable materials.

10 On a piece of backing laminate (Scotch Pak 1109, 3M Co.), a layer of adhesive solution (Duro-Tak 80-1054, National Starch and Chemical Co.) is applied at the thick-
15 ness of 200 microns. This adhesive solution contains 1% (W/W) estradiol (E2) and 10% (W/W) of n-decyl alcohol (n-DA). The coating of this E2/n-DA adhesive solution is
20 applied to form the peripheral region C as shown in FIG. 18. Coating is performed by using a sophisticated Laboratory Coater (Type LTSV, Werner Mathis AG) which is equipped with
25 specially-designed coating head and micrometers to control the thickness of coating. The peripheral coating C is then dried at 60°C for 10 minutes using Laboratory Dryer (Type LTF, Werner Mathis AG). This peripheral coating is here-
30 after called intermediate product (I). Using the same equipment, a layer of 20% (W/W) polyisobutylene (Oppanol B80, BASF Co.) solution is coated onto the low-adhesion side of release liner (Scotch Pak 1022, 3M Co.) at the thickness
35 of 600 microns. This coating is dried at 50°C for 5 minutes using the same drier used in the previous step. The dried coating of polyisobutylene polymer band is then laminated to
40 the intermediate product (I) and then the release liner is removed to form the region D as shown in Figure 18. The product obtained is thereafter called intermediate product
45 (II). Again, using the same coating equipment, a layer of Duro-Tak (80-1054, National Starch and Chemical Co.) adhe-
50
55

5 sive solution containing 1% (W/W) of levonorgestrel, 10% of
Span 20 (Sigma Chemical Co.), 10% propylene glycol (Fisher
10 Scientific Co.) and 10% of lauric acid (Sigma Chemical Co.)
are coated onto the intermediate product (II) at the thick-
ness of 400 microns. The coating is dried at 60°C for 15
15 minutes in the same drier used in the previous steps. After
the drying is complete, the coating of the three regions is
20 then covered with a release liner (Scotch Pak 1022, 3M Co.).
The product obtained after this step of coating, drying and
lamination processes consists of three concentric regions as
25 shown in FIG. 18. The area ratio of region C over region B,
in this case, is 1.25:1. The long-term (140 hours) in-vitro
30 skin permeation rates of levonorgestrel and estradiol were
found to be 0.52 (± 0.07) and 0.20 (± 0.03) mcg/sq cm/hr,
35 respectively, when adult caucasian female cadaver skin was
used in the in-vitro test procedure. If the area of region
B is 5 sq cm (area of region C becomes 6.25 sq cm) a mr-TCD
40 system of this configuration and size would be able to
simultaneously deliver 62.4 (± 8.4) mcg of levonorgestrel and
30.0 (± 4.5) mcg of estradiol per day. Therefore, ratio of
45 daily delivery rate of levonorgestrel/estradiol is cal-
culated as 2.08.

50 This example illustrates that by controlling the compo-
sition of enhancers, drug loading, thickness of coating area
of each region, the ratio of daily delivery rate of proges-
55 tin/estrogen can be controlled by using the mr-TCD system
described above.

5

10

The shape of the dosage units can be varied. The regions can be parallel strips or have other appropriate shapes and/or configurations.

15

Ethinyl estradiol or other estrogens can be used and the progestins described above can be used instead of 17-beta-estradiol and levonorgestrel, respectively.

20

25

30

35

40

45

50

55

5

What is Claimed is:

10

1. A transdermal dosage unit comprising:

15

a. a backing layer which is impervious to the ingredients of the dosage unit;

20

b. a reservoir layer which has a reservoir region in which there is dissolved in a liquid medium for transdermal absorption one or more pharmaceuticals which are present therein in the form of micro-reservoirs or a macroreservoir;

25

c. the absorption rate of said one or more pharmaceuticals being substantially constant for at least 24 hours and providing by transdermal absorption effective amounts thereof;

30

d. said reservoir region having an outer wall being a permeability-regulating polymer membrane which is substantially non-porous and which provides said substantially constant rate of transdermal absorption of said one or more pharmaceuticals; and

35

40

e. said dosage unit adapted to adhere to a subject using said dosage unit.

45

2. A dosage unit of Claim 1 wherein the reservoir region has said pharmaceuticals present in the form of a macroreservoir region.

50

3. A dosage unit of Claim 2 wherein the reservoir layer has an adhesive region which is separate from said macroreservoir region.

55

5

10

15

20

25

30

35

40

45

50

55

4. A dosage unit of Claim 3 wherein the macroreservoir region has applied thereto an adhesive layer adapted to adhere said dosage unit to said subject.
5. A dosage unit of Claim 1 wherein said reservoir region said pharmaceuticals present in the form of micro-reservoirs.
6. A dosage unit of Claim 5 which further comprises a second region which provides adhesion to said subject.
7. A dosage unit of Claim 1 wherein said reservoir region has an adhesive region which is separate from said reservoir region and has a pharmaceutical dispersed therein in the form of microreservoirs.
8. A dosage unit of Claim 1 wherein said liquid medium is a biocompatible combination of miscible solvents.
9. A dosage unit of Claim 8 wherein one of said solvents is water.
10. A dosage unit of Claim 8 wherein the combination of miscible solvents comprise water and ethyl alcohol.
11. A dosage unit of Claim 1 wherein said liquid medium comprises a C₃-C₄ alkane diol.
12. A dosage unit of Claim 2 wherein the solvent is propylene glycol.

5

13. A transdermal dosage unit comprising:

10

a. a backing layer which is impervious to the ingredients of the dosage unit;

15

b. a reservoir layer which is attached to said backing layer which has multiple regions, at least two of which in use contact the skin of a subject using said dosage unit, and provide transdermal absorption of one or more pharmaceuticals simultaneously.

25

14. A dosage unit of Claim 2, 5 or 13 wherein said pharmaceuticals are selected from hormonal steroids or combinations thereof.

30

35

15. A dosage unit of Claim 2 wherein at least one of said pharmaceuticals is 17-beta-estradiol.

40

16. A dosage unit of Claim 2, 5, 7 or 13 wherein said pharmaceuticals are anti-HIV pharmaceuticals.

45

17. A dosage unit of Claim 2, 5, 7 or 13 wherein said pharmaceuticals are a combination of pharmaceuticals providing combination treatment.

50

18. A dosage unit of Claim 2, 5, 7 or 13 wherein said pharmaceuticals are a combination of a diuretic and an antihypertensive pharmaceutical providing combination therapy.

55

- 5
10
15
20
25
30
35
40
45
50
55
19. A dosage unit of Claim 2, 5, 7 or 13 wherein said dosage unit has an effective amount of one or more transdermal absorption enhancers.
20. A dosage unit of Claim 19 wherein said transdermal absorption enhancer is selected from the group consisting of long chain alkanoic acids, long chain alkanols, alkyl esters of lactic acids and combinations thereof.
21. A dosage unit of Claim 1 wherein membrane is a substantially non-porous ethylene/vinyl acetate film.
22. A process for transdermally administering one or more pharmaceuticals by use of a dosage unit of Claim 2, 5, 7 or 13.

1/18




FIG. 1

2/18




FIG. 2




FIG. 3

4/18




FIG. 4

5/18




FIG. 5

6/18




FIG. 6

7/18




FIG. 7

8/18




FIG. 8

9/18




FIG. 9

10/18




FIG. 10

11/18

EVA MEMBRANE (VAc 28% 50 μ m)
HAIRLESS RAT SKIN (FEMALE, DORSAL)
Sat'd LNG (2% OA/70% EtOH)




FIG. 11

12/18

EVA MEMBRANE (VAc 28% 50 μ m)
HAIRLESS RAT SKIN (FEMALE, DORSAL)
Sat'd LNG (2% OA/70% EtOH)




FIG. 12

13/18




FIG. 13

14/18




FIG. 14

15/18

EVA MEMBRANE (VAc 28% 50 μm)
Sat'd LNG (2% OA/70% EtOH)
HUMAN CADAVER SKIN (FEMALE, 34YRS)




FIG. 15

16/18




FIG. 16

17/18

LNG/EtOH (70%)(21.84 $\mu\text{g}/\text{cm}^2$ /DAY)
EVA MEMBRANE (28% VAc; 50 μm)
E₂ / POLYACRYLATE (24.36 $\mu\text{g}/\text{cm}^2$ /DAY)




FIG. 17

18/18




FIG. 18

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/08714

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61F 13/02, 13/00

US CL : 424/448, 449

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/448, 449

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,818,540 (CHIEN ET AL) 04 APRIL 1989, see entire document.	1-22
A	US, A, 5,023,084 (CHIEN ET AL) 11 JUNE 1991, see columns 8-18.	1-22



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

26 OCTOBER 1993

Date of mailing of the international search report

15 DEC 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

J. VENKAT

Telephone No. (703) 308-2351

